Oura, the company behind the popular Oura Ring health tracker, has indefinitely postponed its planned Initial Public Offering (IPO) that was set to raise up to $2.2 billion. The move reflects broader jitters in the IPO market, with the company citing uncertain conditions as the reason for pausing the process. The decision puts on hold the IPO that had been filed to offer 55 million shares at a proposed $40 to $44 each, which would have pegged the company’s valuation at roughly $15 billion at the mid-point.
Strong Growth, But Timing Isn’t Right
Despite the IPO delay, Oura has been on a strong growth trajectory. The company reported having 5.7 million paying members, up from 5 million at the end of June. It expects its 2026 revenue to increase by about 90 percent compared to the prior year, when it brought in $907.9 million in revenue. While its recurring revenue—primarily from memberships—covers roughly one-fifth of total sales, those subscriptions carry an impressive 89 percent gross margin. Most of its revenue still comes from hardware sales.
At the same time, Oura is financially solid. As of the end of June, it had $372 million in cash reserves. The IPO proceeds were intended to help cover tax obligations tied to employee share grants that would have vested upon listing.
Stakeholders and Valuation Impacted
The IPO was not just about raising new funds—it was also meant to provide liquidity for early investors. For example, Forerunner Ventures had planned to sell its entire 9.3 percent stake, potentially securing about $1.20 billion if the IPO price matched the $42 midpoint. The delay means shareholders seeking liquidity will have to wait.
Oura’s valuation has jumped rapidly over the past year. Last October, the company raised $900 million in a funding round led by Fidelity, valuing it around $11 billion—nearly double what it was worth less than a year earlier.
The company’s CEO emphasized that while the IPO postponement halts that specific path forward, it doesn’t change its broader mission. Oura plans to continue growth through its existing operations and is waiting for what it believes will be the right moment to move ahead.
This comes at a time when many tech companies are re-evaluating plans to go public. IPO windows have widened and narrowed sharply, with macroeconomic factors, interest rates, and investor sentiment weighing heavily. For Oura, strong demand for its premium health ring and subscription services still position it well—but the market’s mood makes timing everything.
Why this matters: Oura’s delay highlights how even companies with solid revenue, a strong product, and growing membership base can face headwinds when markets turn uncertain. For those watching the wearables, health tech, or subscription models, this signals that valuations and timing are fragile. Keep an eye on how Oura adjusts its strategy: will it push for a dual path of growth without IPO, or launch when conditions improve? Either way, it’s a test of discipline and conviction in an uncertain public markets landscape.
